GILD

Business profile & competitive position

Gilead Sciences, Inc. (GILD) is classified in the Healthcare sector under the Drug Manufacturers – General industry. It is a large-cap biopharma company with a current market capitalization of $187.5 billion, a scale that places it among the biggest names in its peer group. In plain terms, Gilead discovers, develops and commercializes medicines, historically anchored in antiviral and oncology franchises.

The current margin and return figures, however, do not point to a wide, cash-generative moat at this exact moment. The trailing net margin is –10.6% and return on equity is –16.3%. Persistent negative profitability and a negative ROE generally signal that the business is consuming capital rather than compounding it. Those numbers do not support a claim of durable pricing power on their own; instead, they suggest Gilead is in a product-cycle transition, absorbing costs from launches, acquisitions or patent erosion while investors price in future pipeline outcomes.

Financial posture

Gilead’s valuation metrics are unusual because of those losses. The stock trades around $150.995, yet the P/E ratio sits at –58.1. A negative P/E simply reflects negative trailing earnings; it is not a useful valuation shortcut here. The net margin of –10.6% confirms that the company has recently spent more than it earned on a GAAP basis, while the –16.3% ROE shows book-value returns have turned negative.

At the same time, the stock’s five-year beta is 0.35, which is unusually low. That reading is consistent with large, established drugmakers whose equity tends to move less aggressively than the broader market, even when earnings are volatile. From a technical snapshot, Gilead’s RSI is 67.7 and price is well above the 50-day exponential moving average of $139.12. Those are descriptive observations about recent momentum, not directional guidance.

Macro & geopolitical exposure

As a Drug Manufacturers – General company, Gilead carries the macro and policy exposures typical of the industry rather than any firm-specific supply-chain detail we can verify from the data. These include:

• Regulatory and FDA risk: Approval timelines, label expansions and safety actions directly affect revenue trajectories.
• Drug-pricing and reimbursement policy: Legislation touching Medicare negotiation, rebate rules or international reference pricing can compress realized prices.
• Patent cliffs and exclusivity: Loss of market exclusivity on key brands can reshape revenue quickly.
• Trade, tariffs and API supply chains: Global supply chains for active pharmaceutical ingredients and finished goods remain sensitive to cross-border trade policy.
• Currency translation: A large multinational pharma revenue base is exposed to dollar strength or weakness.
• R&D tax and capital rules: Changes in how R&D is expensed or capitalized can swing reported margins and cash-flow timing.

These are structural risks of the industry classification itself and are worth monitoring regardless of the company’s specific pipeline mix.

Recent developments

The most recent news flow has centered on approvals, capital allocation and price action:

• On 2026-09-07, defenseworld.net reported that Compass Financial Management LLC invested $671,000 in Gilead Sciences, a modest institutional accumulation that indicates ongoing buyer interest.
• A 2026-09-05 fool.com headline noted that Gilead had won its third FDA approval in less than four months, framing the stock as a potential turnaround narrative.
• On 2026-09-04, 247wallst.com asked whether Gilead’s increasingly large checks—likely referring to deal-making or share buybacks—can keep being funded by its drug portfolio.
• A 2026-09-03 zacks.com piece highlighted that Gilead was up 13.6% since its last earnings report.

Taken together, the headlines show a company delivering new regulatory wins—but also facing scrutiny over whether those wins can finance an ambitious capital-allocation strategy.

Earnings behavior & post-earnings drift

Gilead’s earnings history over the last eight quarters is strikingly consistent: it has beaten estimates 8 out of 8 times, for a 100% beat rate, with an average earnings surprise of 9.7%. More importantly for short-term traders and event-studies, the average 5-day price move following earnings has been +1.71%, with the drift classified as “up.”

The most recent four reported quarters look like this, most recent first:

• 2026-08-04: actual EPS of –$6.75 versus estimate –$7.25, a 6.9% surprise. The stock fell –2.58% the next day but drifted +0.38% over the following five sessions.
• 2026-05-07: actual EPS of $2.03 versus estimate $1.91, a 6.3% surprise. The next-day move was –2.04%, with a five-day drift of –1.49%.
• 2026-02-10: actual EPS of $1.86 versus estimate $1.81, a 2.8% surprise. The stock gained 5.82% the next day and 3.74% over five days.
• 2025-10-30: actual EPS of $2.47 versus estimate $2.13, a 16% surprise. The next-day move was +1.14%, followed by a five-day drift of +4.19%.

The immediate next-day reactions have been inconsistent, but the longer five-day drift has averaged positive. Going forward, Gilead’s next scheduled report is 2026-10-29 after the close, with a current consensus EPS estimate of $2.15. The market’s real expectation will be shaped by both that formal estimate and whatever unofficial consensus has developed around pipeline updates and margin trends.

For a deeper synthesis of institutional sentiment, revenue forecasts and valuation models beyond the headline numbers, readers can view the full institutional verdict on Gilead Sciences.